Advertisement

Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX

      Abstract

      Purpose

      We aimed to 1) describe characteristics of patients with heart failure with preserved ejection fraction (HFpEF) enrolled in RELAX stratified by normal or elevated baseline serum uric acid (sUA) level; 2) evaluate the association between sUA level and surrogate clinical measures; and 3) assess associations between changes in sUA level over time and changes in surrogate clinical measures.

      Methods

      We analyzed 212 patients with HFpEF and normal or elevated (>6 mg/dL) baseline sUA measurements from the RELAX trial. Variables examined included clinical characteristics, cardiopulmonary exercise testing, 6-minute walk testing, quality of life, echocardiography, and serum biomarker testing. Baseline characteristics between groups were compared and scatter plots with quadratic regression lines and linear regression modeling were used to assess the relationship between baseline sUA and clinical measures. Kaplan–Meier curves were used to describe composite death or cardiovascular/renal hospitalization.

      Results

      The prevalence of elevated baseline sUA was 68.9%. Patients with elevated sUA had more baseline comorbidities and poorer functional status on cardiopulmonary exercise testing than those without. After adjustment, significant associations between baseline sUA levels and cystatin C, N-terminal pro B-type natriuretic peptide, high-sensitivity troponin I, and high-sensitivity C-reactive protein were identified. Higher baseline sUA was also associated with worsening peak VO2, 6-minute walk testing, and left ventricular mass. No significant association was found between baseline sUA levels and the composite of death or cardiovascular/renal hospitalization at 24 weeks.

      Conclusion

      sUA is an important marker of comorbidities and functional status in patients with HFpEF. Clinical trials of sUA-lowering therapies in patients with HFpEF are promising.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Redfield MM
        • Chen HH
        • Borlaug BA
        • et al.
        Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
        JAMA. 2013; 309: 1268-1277
        • Shimizu T
        • Yoshihisa A
        • Kanno Y
        • et al.
        Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction.
        Am J Physiol Heart Circ Physiol. 2015; 309 (H1123-H1129)
        • Palazzuoli A
        • Ruocco G
        • De Vivo O
        • Nuti R
        • McCullough PA
        Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction.
        Am J Cardiol. 2017; 120: 1146-1150
        • Palazzuoli A
        • Hashemi H
        • Jameson LC
        • McCullough PA
        Hyperuricemia and cardiovascular disease.
        Rev Cardiovasc Med. 2017; 18: 134-145
        • Ibrahim NE
        • Januzzi Jr, JL
        Established and emerging roles of biomarkers in heart failure.
        Circ Res. 2018; 123: 614-629
        • Pagidipati NJ
        • Hess CN
        • Clare RM
        • et al.
        An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome.
        Am Heart J. 2017; 187: 53-61
        • Pagidipati NJ
        • Clare RM
        • Keenan RT
        • Chiswell K
        • Roe MT
        • Hess CN
        Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease.
        J Am Heart Assoc. 2018; 7e009328
        • Givertz MM
        • Anstrom KJ
        • Redfield MM
        • et al.
        Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study.
        Circulation. 2015; 131: 1763-1771
        • Ogino K
        • Kinugasa Y
        • Kato M
        • Yamamoto K
        • Hamada T
        • Hisatome I
        Uric-acid lowering treatment by a xanthine oxidase inhibitor improved the diastolic function in patients with hyperuricemia.
        J Card Fail. 2019; 25: S26